{
    "doi": "https://doi.org/10.1182/blood.V126.23.2874.2874",
    "article_title": "Colony-Forming Unit Cell (CFU-C) Assays in Myelodysplastic Syndrome ",
    "article_date": "December 3, 2015",
    "session_type": "637. Myelodysplastic Syndromes - Clinical Studies: Poster II",
    "abstract_text": "Introduction: The myelodysplastic syndromes (MDS) are a group of clonal diseases derived from hematopoietic stem cells (HSC). Colony-forming unit cell (CFU-C) assay is an effective method to study the number and the function of HSC in vitro. In this study, we focus on the characteristics and the prognostic value of CFU-C in patients with MDS. Patients and Method: CFU-C assays were performed according to the protocol of MethoCult TM H4435 Enriched (STEMCELL Technologies). A colony was defined as an aggregate of >40 cells. Clusters consisted of 4 to 40 cells. 560 consecutive newly-diagnosed, untreated subjects with MDS diagnosed from March, 2001 to April, 2013 were studied. All subjects were reclassified according to the 2008 WHO criteria. 535 subjects with evaluable cytogenetics were classified using the International Prognostic Scoring System (IPSS) and the revised International Prognostic Scoring System (IPSS-R) criteria. Follow-up data were available for 470\u00a3\u00a884%\u00a3\u00a9subjects. Median follow-up of survivors was 26 months (range, 1-170) months. Subjects receiving an allotransplants were censored in survival analyses. Erythroid and myeloid colonies were isolated from each subject with one cytogenetic abnormality such as del(5/5q-) or +8. Cytogenetic abnormalities of each colony were analyzed by fluorescence i n situ hybridization (FISH). SPSS 17.0 software was used to make statistical analysis. Results: Frequencies of burst-forming units-erythroid (BFU-E), colony forming unit-erythroid (CFU-E) and colony forming unit-granulocytes/macrophages (CFU-G/M) were significantly lower than normals (P0.6) was associated with poor-risk cytogenetics (Table 2) and with worse overall survival in univariable (Figure 1, P=0.001) and multivariable analyses (HR 1.748, [1.01-3.0]; P=0.046) after adjusting for IPSS. Conclusions : These data suggest abnormalities of proliferation and differentiation of erythroid and myeloid precursor cells in vitro parallel the ineffective hematopoiesis typical of MDS and may be useful in predicting outcomes of patients with MDS. Table 1. CFU-C in MDS subtypes  . N . BFU-E . CFU-E . CFU-G/M . N . Ratio of cluster- to CFU-G/M . RA 21 8 (0-44) 40 (0-134) 14 (0-127) 1  6 0.25 (0.40-1.00) RT 4 18 (4-55) 75 (60-90) 1  30 (18-70) 1  2 2  RARS 27 12 (0-33) 35 (1-140) 12 (0-70) 1  10 0.45 (0.17-0.80) RCMD 275 10 (0-80) 33 (0-178) 14 (0-100) 126 0.35 (0-0.83) RAEB1 112 10 (0-258) 32 (0-312) 14 (0-89) 53 0.47 (0-1.00) RAEB2 103 9 (0-46) 25 (0-120) 13 (0-72) 42 0.37 (0-1.00) MDS-U 15 4 (0-58) 25 (0-161) 10 (0-43) 3 2  Del(5q) 3 2 (2-4) 15 (0-20) 5 (5-41) 1  1 2  . N . BFU-E . CFU-E . CFU-G/M . N . Ratio of cluster- to CFU-G/M . RA 21 8 (0-44) 40 (0-134) 14 (0-127) 1  6 0.25 (0.40-1.00) RT 4 18 (4-55) 75 (60-90) 1  30 (18-70) 1  2 2  RARS 27 12 (0-33) 35 (1-140) 12 (0-70) 1  10 0.45 (0.17-0.80) RCMD 275 10 (0-80) 33 (0-178) 14 (0-100) 126 0.35 (0-0.83) RAEB1 112 10 (0-258) 32 (0-312) 14 (0-89) 53 0.47 (0-1.00) RAEB2 103 9 (0-46) 25 (0-120) 13 (0-72) 42 0.37 (0-1.00) MDS-U 15 4 (0-58) 25 (0-161) 10 (0-43) 3 2  Del(5q) 3 2 (2-4) 15 (0-20) 5 (5-41) 1  1 2  1 No significant difference compared with normals. 2 Too few cases to analyze. View Large Table 2. Associations between CFU-C and clinical and laboratory variables  . N . BFU-E . P . CFU-E . P . CFU-G/M . P . Number . Ratio of cluster- to CFU-GM . P . IPSS   0.064  0.006  0.361   0.089 Low 30 13 (0-44)  60 (0-169)  19 (0-45)  10 0.44 (0.24-0.70)  Int-1 361 10 (0-258)  33 (0-312)  14 (0-127)  150 0.33 (0-1.00)  Int-2 115 9 (0-61)  30 (0-137)  14 (0-72)  52 0.45 (0-1.00)  High 29 7 (0-34)  21 (0-93)  12 (0-67)  12 0.44 (0-1.00)  IPSS-R   0.003  0.003  0.125   0.209 Very low 7 16 (9-25)  30 (15-120)  18 (5-33)  2 0.29 (0.10-0.49)  Low 130 14 (0-80)  42 (0-178)  17 (0-70)  48 0.31 (0-0.77)  Intermediate 173 10 (0-66)  34 (0-161)  13 (0-127)  81 0.37 (0-1.00)  High 139 9 (0-259)  29 (0-312)  11 (0-89)  51 0.33 (0-1.00)  Very high 86 8 (0-61)  25 (0-137)  14 (0-91)  42 0.47 (0-1.00)  Cytogenetics (IPSS)   0.867  0.055  0.290   0.007 Good 327 10 (0-258)  36 (0-312)  15 (0-89)  133 0.33 (0-1.00)  Intermediate 133 10 (0-69)  30 (0-162)  12 (0-127)  63 0.45 (0-1.00)  Poor 75 10 (0-61)  25 (0-137)  14 (0-91)  28 0.42 (0-1.00)  Cytogenetics (IPSS-R)   0.990  0.090  0.676   0.022 Very good 7 11 (4-20)  48 (1-110)  14 (8-28)  2 0.49 (0.43-0.56)  Good 324 10 (0-258)  35 (0-312)  15 (0-89)  132 0.33 (0-1.00)  Intermediate 129 10 (0-69)  30 (0-162)  12 (0-127)  62 0.45 (0-1.00)  Poor 27 10 (0-61)  35 (0-137)  16 (0-48)  8 0.36 (0.15-1.00)  Very poor 48 11 (0-42)  22 (0-120)  14 (0-91)  20 0.53 (0-1.00)  . N . BFU-E . P . CFU-E . P . CFU-G/M . P . Number . Ratio of cluster- to CFU-GM . P . IPSS   0.064  0.006  0.361   0.089 Low 30 13 (0-44)  60 (0-169)  19 (0-45)  10 0.44 (0.24-0.70)  Int-1 361 10 (0-258)  33 (0-312)  14 (0-127)  150 0.33 (0-1.00)  Int-2 115 9 (0-61)  30 (0-137)  14 (0-72)  52 0.45 (0-1.00)  High 29 7 (0-34)  21 (0-93)  12 (0-67)  12 0.44 (0-1.00)  IPSS-R   0.003  0.003  0.125   0.209 Very low 7 16 (9-25)  30 (15-120)  18 (5-33)  2 0.29 (0.10-0.49)  Low 130 14 (0-80)  42 (0-178)  17 (0-70)  48 0.31 (0-0.77)  Intermediate 173 10 (0-66)  34 (0-161)  13 (0-127)  81 0.37 (0-1.00)  High 139 9 (0-259)  29 (0-312)  11 (0-89)  51 0.33 (0-1.00)  Very high 86 8 (0-61)  25 (0-137)  14 (0-91)  42 0.47 (0-1.00)  Cytogenetics (IPSS)   0.867  0.055  0.290   0.007 Good 327 10 (0-258)  36 (0-312)  15 (0-89)  133 0.33 (0-1.00)  Intermediate 133 10 (0-69)  30 (0-162)  12 (0-127)  63 0.45 (0-1.00)  Poor 75 10 (0-61)  25 (0-137)  14 (0-91)  28 0.42 (0-1.00)  Cytogenetics (IPSS-R)   0.990  0.090  0.676   0.022 Very good 7 11 (4-20)  48 (1-110)  14 (8-28)  2 0.49 (0.43-0.56)  Good 324 10 (0-258)  35 (0-312)  15 (0-89)  132 0.33 (0-1.00)  Intermediate 129 10 (0-69)  30 (0-162)  12 (0-127)  62 0.45 (0-1.00)  Poor 27 10 (0-61)  35 (0-137)  16 (0-48)  8 0.36 (0.15-1.00)  Very poor 48 11 (0-42)  22 (0-120)  14 (0-91)  20 0.53 (0-1.00)  View Large Figure 1. View large Download slide Overall survival in subjects with cluster- to CFU-G/M ratios \u00a1\u00dc or > 60%. Figure 1. View large Download slide Overall survival in subjects with cluster- to CFU-G/M ratios \u00a1\u00dc or > 60%.  Close modal Disclosures No relevant conflicts of interest to declare.",
    "topics": [
        "myelodysplastic syndrome",
        "prostatic hypertrophy risk score",
        "follow-up",
        "crossbreeding",
        "cytopenia, refractory, with multilineage dysplasia",
        "refractory anemia with sideroblasts",
        "risk reduction",
        "transplantation, homologous",
        "chromosome abnormality",
        "nucleic acid hybridization"
    ],
    "author_names": [
        "Bing Li, MD",
        "Jinqin Liu",
        "Shiqiang Qu, MD",
        "Robert Peter Gale, MD PhD DSc",
        "Ruixian Xing",
        "Tiejun Qin",
        "Yue Zhang, MD",
        "Zefeng Xu, MD",
        "Liwei Fang",
        "Hongli Zhang, MD",
        "Lijuan Pan",
        "Naibo Hu",
        "Gang Huang, PhD",
        "Zhijian Xiao, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Bing Li, MD",
            "author_affiliations": [
                "MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Jinqin Liu",
            "author_affiliations": [
                "State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Shiqiang Qu, MD",
            "author_affiliations": [
                "MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Robert Peter Gale, MD PhD DSc",
            "author_affiliations": [
                "Imperial College, London, United Kingdom "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ruixian Xing",
            "author_affiliations": [
                "MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Tiejun Qin",
            "author_affiliations": [
                "MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Yue Zhang, MD",
            "author_affiliations": [
                "State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Zefeng Xu, MD",
            "author_affiliations": [
                "State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Liwei Fang",
            "author_affiliations": [
                "MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Hongli Zhang, MD",
            "author_affiliations": [
                "MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lijuan Pan",
            "author_affiliations": [
                "MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Naibo Hu",
            "author_affiliations": [
                "MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gang Huang, PhD",
            "author_affiliations": [
                "Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Zhijian Xiao, MD",
            "author_affiliations": [
                "State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-04T15:35:30",
    "is_scraped": "1"
}